Why the study?
Does oral sulodexide improve fibrinolysis and coagulation parameters in healthy volunteers?
Does oral sulodexide improve fibrinolysis and coagulation parameters in healthy volunteers?
Oral sulodexide demonstrates significant pro-fibrinolytic and antithrombotic activity without affecting the intrinsic coagulation pathway in healthy volunteers.
Answers are grounded in this paper and cite their sources.
Supports oral sulodexide dosing for antithrombotic effects without aPTT impact; extends prior data to repeated administration and warrants patient trials.
Eight male and 8 female healthy volunteers, aged on average 32 +/- 6 years, underwent a randomized, crossover study, aimed at comparing the activity on some fibrinolysis and coagulation parameters of 100 and 200 mg/day of oral sulodexide, administered as enteric-coated tablets. After the single and the repeated (for 7 days) administration of the two daily dosages, the Fibrin Plates test, the Heptest, the Plasminogen Activator Inhibitor test (as to both activity and antigen level) and the activated Partial Thromboplastin Time were checked during the first 6 hours after administration. The pro-fibrinolytic and antithrombotic activity of sulodexide was confirmed to be significant with both dosage schemes and potentiated by repeated administrations. On the other hand, the absence of any influence on aPTT confirmed the lack of interference of the drug, after oral administration, on the intrinsic pathway of coagulation. No adverse reactions or events were observed.
No takes yet. Share an insight, caveat, or question.
Palmieri et al. (1993) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: